FIG. 1



Post-biopsy NAFLD Activity Score
p< 0.05 One-way Anova for all groups except OCA and 0.1 mg/Kg Compound 1
NAS (0-8)
0
2
4
6
8
Vehicle
Obeticholic acid (30 mg/kg)
Compound 1 (0.1 mg/Kg)
Compound 1 (0.3 mg/Kg)
Compound 1 (1 mg/Kg)

FIG. 2



% of Animals Showing Fibrosis Improvement
% with 1-2 stage decrease
60
40
20
0
Vehicle
Obeticholic acid (30 mg/Kg)
Compound 1 (0.1 mg/Kg)
Compound 1 (0.3 mg/Kg)
Compound 1 (1 mg/Kg)

FIG. 3A



Liver Triglycerides
mg/g liver
150
100
50
0
Vehicle
Obeticholic acid (30 mg/Kg)
Compound 1 (0.1 mg/Kg)
Compound 1 (0.3 mg/Kg)
Compound 1 (1 mg/Kg)

FIG. 3B



Liver Cholesterol
mg/g liver
40
30
20
10
0
Vehicle
Obeticholic acid (30 mg/Kg)
Compound 1 (0.1 mg/Kg)
Compound 1 (0.3 mg/Kg)
Compound 1 (1 mg/Kg)

FIG. 4



Change in Body Weight From Baseline
% Change in Body Weight from baseline
20
10
0
-10
-20
1st dose
0
5
10
15
20
25
30
35
40
45
50
Time (days)
Naive
Vehicle
Anti-IL-12
Compound 1 (0.1 mg/Kg)
Compound 1 (0.3 mg/Kg)
Compound 1 (1 mg/Kg)

FIG. 5



Full Colon Weight to Length Ratio
* p<0.0001, vs Vehicle,
One-Way ANOVA with Dunnett's post test
Colon weight/length (mg/cm)
80
60
40
20
0
*
*
*
*
Naive
Vehicle
Anti-IL-12/23, D21-48
Compound 1 (0.1 mg/Kg), D21-48
Compound 1 (0.3 mg/Kg), D21-48
Compound 1 (1 mg/Kg), D21-48

FIG. 6



Full Colon Histopathology Sum Score
* p<0.0001, vs Vehicle,
One-Way ANOVA with Dunnett's post test
Sum Score (0-20)
10
8
6
4
2
0
*
*
*
*
Naive
Vehicle
Anti-IL-12/23, D21-48
Compound 1 (0.1 mg/Kg), D21-48
Compound 1 (0.3 mg/Kg), D21-48
Compound 1 (1 mg/Kg), D21-48

FIG. 7



Compound 1 Drug plasma levels (day 7)
Plasma Conc. (µg/mL, Mean ± SD)
1
0.1
0.01
0.001
0
4
8
12
16
20
24
Time (hr)
0.3 mg/Kg
1.0 mg/Kg
3.0 mg/Kg

FIG. 8



Day 7 C4 plasma levels
C4 (µg/mL, Mean ± SD)
0.010
0.005
0.000
0
12
24
Time (hr)
Vehicle
Compound 1 (0.3 mg/Kg)
Compound 1 (1 mg/Kg)
Compound 1 (3 mg/Kg)

FIG. 9



Day 14 Pharmacokinetics
Plasma Conc. (µg/mL, Mean ± SD)
0.1
0.01
0.001
0
6
12
18
24
Time (hr)
5 mg
10 mg

FIG. 10




Day 14 Pharmacodynamics (C4)
Placebo
5 mg
10 mg
C4 (ng/mL)
40
30
20
10
0
0
6
12
18
24
Time (hr)

FIG. 11


Daily changes in C4 levels in plasma
Placebo
2.5 mg
5 mg
7.5 mg
10 mg
C4 (ng/mL)
60
40
20
0
0
7
14
Study Day